AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 1 analysts
Fundamentals
Fundamentals institutional score is 100 using EVA spread proxy 76.0%; growth durability 99.5.
Valuation
Valuation institutional score is 83 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 97 using mean target upside 28.6%; dispersion penalty 0; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 47 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
This data source has not been supplied for the decision payload.
Signal Summary
Market intelligence remains Supportive. fundamentals and valuation provide support, while technical structure remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 2.9% below historical median. Valuation is stable — currently in the strongly undervalued zone (z-score: -0.49). Confidence: 94%.
Live forward EPS implies next-12-month EPS of ₹133.90. Applying the stock's normalized valuation corridor produces a fair range of ₹5,299.76 to ₹5,588.99, with base value near ₹5,445.71 (+19.6% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹133.90
Forward P/E
34.0x
Base Fair Value
₹5,445.71
Fair Range
₹5,299.76 - ₹5,588.99
Upside To Base
+19.6%
Estimate Source
Live forward EPS
Growth Estimate
+13.3%
5Y Average
40.66
Current
39.47
Overvalued
41.74
Undervalued
39.58
5Y Average
29.46
Current
28.61
Overvalued
30.14
Undervalued
28.50
5Y Average
11.37
Current
11.06
Overvalued
13.08
Undervalued
9.67
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Undervalued | -50% vs avg | +22.8% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 27.5x Undervalued | -56% vs avg | +43.2% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 43.6x Undervalued | -30% vs avg | +51.8% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.6x Undervalued | -30% vs avg | -25.8% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 38.8x Undervalued | -38% vs avg | +22.5% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.5x Undervalued | -38% vs avg | +30.0% |
ASTRAZENECA PHARMA IND LT ASTRAZENPharmaceuticals | +20.4% | 8.2% | 106.8x Premium | +72% vs avg | -6.7% |
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 167.5x Premium | +169% vs avg | -52.5% |
SANOFI CONS HEALTHC IND L trades at a discount (39.5x vs peer avg 62.2x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include CAPLIN POINT LAB LTD., ALIVUS LIFE SCIENCES LTD, AKUMS DRUGS AND PHARMA L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹229 CrMar 2026Latest net profit
₹68 CrMar 2026Latest EPS
₹29.44Mar 2026Net margin
37.4%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 100 | 210 | 225 | 222 | 164 | 160 | 171 | 173 | 221 | 234 | 251 | 229 |
| Expenses | 65.6 | 116 | 135 | 140 | 101 | 96.8 | 109 | 109 | 151 | 149 | 159 | 140 |
| Operating Profit | 34.3 | 93.9 | 88.8 | 80.9 | 62.5 | 61.6 | 61.1 | 62 | 67.2 | 81.7 | 88.8 | 85.6 |
| OPM % | 34.2% | 44.65% | 39.54% | 36.51% | 38.02% | 38.52% | 35.79% | 35.92% | 30.42% | 34.93% | 35.38% | 37.35% |
| Other Income | 0.2 | 1.3 | 2.6 | 3 | 0.8 | 4.2 | 5 | 5.2 | 5.6 | 3 | 4.6 | 5.6 |
| Interest | — | — | — | — | 0.1 | 3.4 | 0.4 | 0.4 | 0.5 | 0.6 | 0.5 | 0.5 |
| Depreciation | 0.4 | 0.7 | 0.7 | 0.9 | 1.1 | 1.5 | 1 | 2 | 3 | 3.3 | 3.4 | 3.2 |
| Profit before tax | 34.5 | 95.2 | 91.4 | 83.9 | 63.2 | 62.4 | 65.7 | 66.8 | 72.3 | 84.1 | 92.9 | 90.7 |
| Tax % | 25.22% | 25.21% | 23.74% | 25.27% | 15.66% | 25.96% | 28.16% | 25.15% | 25.17% | 25.21% | 25.83% | 25.25% |
| Net Profit | 25.8 | 71.2 | 69.7 | 62.7 | 53.3 | 46.2 | 47.2 | 50 | 54.1 | 62.9 | 68.9 | 67.8 |
| EPS in Rs | 11.19 | 30.92 | 29.48 | 27.22 | 12.58 | 19.52 | 19.25 | 21.69 | 26.36 | 27.31 | 28.87 | 29.44 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.